Bevespi Aerosphere
·
- Prescription status not stated
- Breathing, airways, allergies and cough
- Active substance
- Glycopyrronium;formoterol fumarate dihydrate
- Made by
- AstraZeneca AB
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | AstraZeneca AB |
|---|---|
| Active substance | Glycopyrronium;formoterol fumarate dihydrate |
| Used in | Breathing, airways, allergies and cough |
| Classification | R03AL07 · Breathing, airways, allergies and cough |
| Authorised on | 2018-12-18 |
| Last updated by the regulator | 2024-12-03 |
| EMA product number | EMEA/H/C/004245 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).